Program
betamethasone dipropionate
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.
Drug pageBetamethasone dipropionate: every studyMany companies study it; this page follows only the 26 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharmaits history only | 180 open or running | phase 4since Nov 3, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeuticsits history only | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Primus Pharmaceuticalsits history only | 10 open or running | phase 4since Apr 13, 2016 | Apr 13, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 15, 2005.
- Aug 27, 2013Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT01935869 · 224 enrolled · France
- Jan 27, 2015Phase 1 study in Skin and Connective Tissue DiseasesLEO Pharma · NCT02355639 · 16 enrolled · Germany
- Feb 25, 2015Phase 1 study in Dermatitis, AtopicLEO Pharma · NCT02376049 · 30 enrolled · Canada, Israel
- Mar 12, 2015Phase 2 study in Psoriasis VulgarisLEO Pharma · NCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
- Apr 13, 2016Primus Pharmaceuticals’ first study: phase 4 study in Plaque PsoriasisNew to Primus PharmaceuticalsPrimus Pharmaceuticals · NCT02749799 · 45 enrolled · United States
- Nov 22, 2016Phase 1 study in Psoriasis VulgarisLEO Pharma · NCT02973776 · 36 enrolled · France
- Oct 9, 2017MC2 Therapeutics’ first study: phase 3 study in Psoriasis VulgarisNew to MC2 TherapeuticsMC2 Therapeutics · NCT03308799 · 794 enrolled · United States
- Nov 1, 2017Glenmark Pharmaceuticals Ltd. India’s first study: phase 3 study in Scalp PsoriasisNew to Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals Ltd. India · NCT03331523 · 643 enrolled · United States
- Feb 20, 2018Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03462927 · 63 enrolled · United States
- Nov 13, 2018Phase 1 study in VasoconstrictionMC2 Therapeutics · NCT03758365 · 36 enrolled · France
- Jan 10, 2019Phase 3 study in Psoriasis VulgarisMC2 Therapeutics · NCT03802344 · 498 enrolled · Czechia, Germany
- Jan 11, 2019Phase 2 study in Psoriasis VulgarisMC2 Therapeutics · NCT03819218 · 7 enrolled · Czechia, Germany
- Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisLEO Pharma · NCT05919082 · 604 enrolled · China
- Dec 11, 2025Huadong Medicine’s first study: phase 3 study in Plaque PsoriasisNew to Huadong MedicineHuadong Medicine · NCT07357831 · 539 enrolled · China
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07357831Plaque Psoriasis · China | 3 | Completed | Huadong Medicine | Aug 6, 2026 | 539 |
| NCT05919082Stable Plaque Psoriasis · China | 3 | Completed | LEO Pharma | Feb 23, 2024 | 604 |
| NCT03819218Psoriasis Vulgaris · Czechia, Germany | 2 | Terminated | MC2 Therapeutics | Dec 11, 2020 | 7 |
| NCT03802344Psoriasis Vulgaris · Czechia, Germany | 3 | Completed | MC2 Therapeutics | Oct 2, 2019 | 498 |
| NCT03758365Vasoconstriction · France | 1 | Completed | MC2 Therapeutics | Nov 23, 2018 | 36 |
| NCT03462927Psoriasis Vulgaris · United States | 2 | Completed | MC2 Therapeutics | Aug 4, 2018 | 63 |
| NCT03331523Scalp Psoriasis · United States | 3 | Completed | Glenmark Pharmaceuticals Ltd. India | Oct 25, 2018 | 643 |
| NCT03308799Psoriasis Vulgaris · United States | 3 | Completed | MC2 Therapeutics | Jun 8, 2018 | 794 |
| NCT02973776Psoriasis Vulgaris · France | 1 | Completed | LEO Pharma | Feb 2017 | 36 |
| NCT02749799Plaque Psoriasis · United States | 4 | Completed | Primus Pharmaceuticals | Jul 2016 | 45 |
| NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more | 2 | Completed | LEO Pharma | Mar 28, 2018 | 117 |
| NCT02376049Dermatitis, Atopic · Canada, Israel | 1 | Completed | LEO Pharma | Jul 2015 | 30 |
| NCT02355639Skin and Connective Tissue Diseases · Germany | 1 | Completed | LEO Pharma | Apr 2015 | 16 |
| NCT01935869Psoriasis Vulgaris · France | 1 | Completed | LEO Pharma | Nov 2013 | 224 |
| NCT01866163Psoriasis Vulgaris · United States | 3 | Completed | LEO Pharma | Oct 2013 | 426 |
| NCT01600222Psoriasis Vulgaris · Canada | 2 | Completed | LEO Pharma | May 2013 | 37 |
| NCT01536938Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 303 |
| NCT01536886Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Sep 2012 | 376 |
| NCT00875277Psoriasis Vulgaris · France | 2 | Completed | LEO Pharma | May 2009 | 24 |
| NCT00817219Psoriasis Vulgaris · United States | 2 | Completed | LEO Pharma | Dec 2011 | 33 |
| NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more | 2 | Completed | LEO Pharma | 360 | |
| NCT00248456Psoriasis Vulgaris · China | 4 | Completed | LEO Pharma | 320 | |
| NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more | 3 | Completed | LEO Pharma | 300 | |
| NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 800 | |
| NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more | 3 | Completed | LEO Pharma | 1,350 | |
| NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more | 3 | Completed | LEO Pharma | 1,485 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “MC2-01 Cream”, 2 entries
- “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 24 studies
- Skin and Connective Tissue Diseases, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.